DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 5,960,732 | $122,969,901 | 14.32% |
| ARCH Venture Management, LLC | 693,749 | $14,312,042 | 9.30% |
| Flagship Pioneering Inc. | 2,619,968 | $54,049,940 | 3.92% |
| Casdin Capital, LLC | 1,300,000 | $26,819,000 | 2.97% |
| Yiheng Capital Management, L.P. | 1,150,684 | $23,738,611 | 1.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 154,000 | $3,172,400 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 254,941 | $5,259,433 | 1.02% |
| Temasek Holdings (Private) Ltd | 6,895,992 | $142,264,315 | 0.85% |
| Clarius Group, LLC | 378,262 | $7,803,545 | 0.74% |
| Artal Group S.A. | 802,899 | $16,564 | 0.71% |
| Cercano Management LLC | 625,000 | $12,893,750 | 0.46% |
| Pier Capital, LLC | 125,080 | $2,580,400 | 0.42% |
| GILDER GAGNON HOWE & CO LLC | 1,246,199 | $25,709,095 | 0.39% |
| Baillie Gifford | 14,681,027 | $302,869,587 | 0.28% |
| Baker Brothers Advisors | 2,292,003 | $47,284,022 | 0.27% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 594,989 | $12,274,623 | 0.27% |
| PIER 88 INVESTMENT PARTNERS LLC | 50,700 | $1,045,941 | 0.26% |
| CONCENTRIC WEALTH MANAGEMENT, LLC | 36,486 | $752,706 | 0.25% |
| HARBOR CAPITAL ADVISORS, INC. | 52,279 | $1,078,516 | 0.23% |
| Eventide Asset Management | 621,850 | $12,828,766 | 0.23% |
External links
This page lists DENALI THERAPEUTICS INC's shareholders in Q3 2023. To view DENALI THERAPEUTICS INC's shareholder history, click here.